Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham
Published . Updated .
This report is about pharma and health.
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story.
- LLY Eli Lilly and+11.9% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- JNJ Johnson & Johnson-0.9% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- PFE Pfizer+8.3% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- MRK Merck+0.3% 13d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | +0.28% | +1.14% | base | after close | after close | after close | after close |
| XBI | +1.83% | +0.75% | base | after close | after close | after close | after close |
| LLY | +0.43% | +2.14% | base | after close | after close | after close | after close |
| JNJ | -2.60% | +0.52% | base | after close | after close | after close | after close |
| PFE | +1.17% | +2.11% | base | after close | after close | after close | after close |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham CNBC
Source: CNBC
Price since this story was published: Select Sector Spdr Tr (XLV)
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | three days earlier | +0.52% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -2.60% | final price |
| Eli Lilly (LLY) | three days earlier | +2.14% | final price |
| Eli Lilly (LLY) | five days earlier | +0.43% | final price |
| Pfizer (PFE) | three days earlier | +2.11% | final price |
| Pfizer (PFE) | five days earlier | +1.17% | final price |
| Spdr Series Trust (XBI) | three days earlier | +0.75% | final price |
| Spdr Series Trust (XBI) | five days earlier | +1.83% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +1.14% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | +0.28% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 31 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 48 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 66 days before publication. Filed 8 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 31 Jul 2026. That is 87 days before publication. Filed 22 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 32 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 68 days before publication. Filed 9 Sep 2026. View the filing.
- Donald J Trump, an executive branch official, sold Merck (MRK), worth $250,001 - $500,000 on 31 Jul 2026. That is 87 days before publication. Filed 22 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies carried with this story
- XLV Select Sector Spdr Tr
In “Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
- XBI Spdr Series Trust
Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 26 Oct 2026 story “Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham.” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
- LLY Eli Lilly
In “Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- JNJ Johnson & Johnson
For “Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 26 Oct 2026 story “Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- MRK Merck
For “Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
The 26 Oct 2026 story “Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham” names Select Sector Spdr Tr (XLV) because of this story.
The link for Select Sector Spdr Tr (XLV) is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
A second company, Spdr Series Trust (XBI), is listed for a different reason: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1131.55 and 1321.17 across 20 sessions. The latest close on file is 1273.69. XBI traded between 152.63 and 158.97 across 2 sessions. The latest close on file is 154.01. XLV traded between 166.19 and 168.74 across 2 sessions. The latest close on file is 167.68.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.